Genentech Defends Herceptin Dosing Patents Before PTAB
Genentech Inc. defended two dosage patents for blockbuster breast cancer drug Herceptin against assertions of obviousness by Hospira Inc. by telling a Patent Trial and Appeal Board panel the Pfizer Inc....To view the full article, register now.
Already a subscriber? Click here to view full article